AKESO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER
Apr 23 20:15 ET
AKESO: Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Apr 8 04:37 ET
AKESO: Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Apr 8 04:34 ET
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2024
Apr 5 05:11 ET
AKESO: Next Day Disclosure Return
Mar 28 08:43 ET
AKESO: COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
Mar 28 08:41 ET
AKESO: PLACING OF NEW SHARES UNDER GENERAL MANDATE
Mar 20 19:56 ET
AKESO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Mar 18 10:52 ET
AKESO: DATE OF BOARD MEETING
Mar 6 04:53 ET
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 29 February 2024
Mar 5 05:06 ET
AKESO: INSIDE INFORMATION ANNOUNCEMENT POSITIVE PROFIT ALERT
Mar 4 18:32 ET
AKESO: CONNECTED TRANSACTION FURTHER INFORMATION IN RELATION TO ACQUISITION OF EQUITY INTEREST IN AD PHARMACEUTICALS
Mar 4 07:35 ET
AKESO: CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF EQUITY INTEREST IN AD PHARMACEUTICALS
Feb 8 18:30 ET
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2024
Feb 6 05:13 ET
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2023
Jan 5 04:21 ET
AKESO: VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTED THE SUPPLEMENTAL NEW DRUG APPLICATION FOR CADONILIMAB (PD-1/CTLA-4) IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR GASTRIC CANCER
Jan 4 19:22 ET
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2023
Dec 6, 2023 04:45 ET
AKESO: VOLUNTARY ANNOUNCEMENT - AK104-303, A PHASE III TRIAL OF CADONILIMAB REACHED PROGRESSION-FREE-SURVIVAL (PFS) PRIMARY ENDPOINT AT INTERIM ANALYSIS FOR FIRST LINE TREATMENT OF CERVICAL CANCER
Nov 22, 2023 18:00 ET
AKESO: VOLUNTARY ANNOUNCEMENT - AK104-302, A PHASE III TRIAL OF CADONILIMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST LINE TREATMENT FOR GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GC/GEJC) REACHED PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS) AT INT
Nov 6, 2023 18:00 ET
AKESO: Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2023
Nov 6, 2023 04:09 ET
No Data
No Data